Here's what we'll cover
Here's what we'll cover
Medicare Is Finally Moving on GLP-1 Coverage
For years, Medicare's coverage of GLP-1 medications for weight loss sat in a frustrating gray area. Drugs like semaglutide and tirzepatide were covered when prescribed for type 2 diabetes, but coverage for obesity alone was largely off the table.
That picture is starting to change. Medicare's GLP-1 program has now reached 700,000 seniors, a milestone that reflects both a policy shift and surging demand among older Americans who want access to these medications. If you're a Medicare beneficiary, or helping a parent navigate coverage, understanding what this expansion means in practical terms matters more than the headline number.
What's Driving the 700K Enrollment Figure
The growth in Medicare GLP-1 enrollment comes from two directions at once.
First, more seniors with type 2 diabetes are accessing GLP-1s through traditional Part D drug coverage. Medications like Ozempic (semaglutide) have been covered for diabetes management for several years, and uptake has accelerated as more doctors and patients recognize the cardiovascular and kidney benefits alongside glucose control.
Second, a separate, newer pathway has opened for weight management specifically. Following a 2025 rule change that allowed Medicare to cover GLP-1s prescribed for obesity, some Part D and Medicare Advantage plans have started adding these drugs to their formularies. Not all plans have moved, and coverage terms vary widely, but the door is now open in a way it simply wasn't before.
Eli Lilly's CEO has pointed to the company holding approximately 70% of this Medicare GLP-1 segment, driven largely by tirzepatide products Mounjaro and Zepbound.
Why Eli Lilly Holds Such a Large Share
Eli Lilly's dominance in the Medicare GLP-1 space doesn't happen by accident.
Mounjaro (tirzepatide) received FDA approval for type 2 diabetes in 2022, and its weight-loss counterpart Zepbound followed in late 2023. Clinical trial data showed tirzepatide producing notably higher average weight loss than semaglutide in head-to-head research, which has influenced both prescriber preferences and patient requests.
Tirzepatide vs. Semaglutide: A Quick Comparison
Beyond clinical outcomes, Lilly has also invested heavily in patient support programs and worked with pharmacy benefit managers to improve formulary positioning. For Medicare patients specifically, tirzepatide's dual coverage pathway (both diabetes and obesity indications) gives it a broader on-ramp than some competing products.
What Medicare Actually Covers: The Details That Matter
Here's where things get complicated. Reaching 700,000 enrolled seniors is a meaningful milestone, but it doesn't mean GLP-1 coverage is automatic or universal for all Medicare beneficiaries.
Coverage Under Medicare Part D
Part D covers prescription drugs, and most GLP-1 medications fall here. For seniors with a type 2 diabetes diagnosis, Ozempic and Mounjaro have been on many formularies for several years. The tricky part is that formulary coverage, copay tiers, and prior authorization requirements differ from plan to plan and year to year.
Coverage for Obesity (No Diabetes Diagnosis)
If you're seeking a GLP-1 for weight management without a diabetes diagnosis, coverage is less consistent. Some Medicare Advantage plans have added Zepbound or Wegovy to their formularies for obesity, but standard Medicare Part D plans vary widely. The 2025 rule change created the legal framework for coverage, but it didn't mandate that every plan add these drugs.
What You'll Still Pay Out of Pocket
Even with coverage, costs aren't zero. Under the Inflation Reduction Act's redesigned Part D benefit, out-of-pocket maximums for 2025 are capped at $2,000 per year. For seniors on high-cost GLP-1s, this cap is important. But you'll still pay something in the form of copays or coinsurance until you reach that cap.
How to Find Out If Your Plan Covers GLP-1s
Knowing the national enrollment figure doesn't tell you whether your specific Medicare plan covers the GLP-1 your doctor wants to prescribe. Here's a practical process for figuring that out.
Step 1: Check Your Plan's Formulary
Every Part D plan publishes a formulary, the list of covered drugs. You can find yours on Medicare.gov or directly on your insurer's website. Search for the drug name and check which tier it falls on. Higher tiers mean higher cost-sharing.
Step 2: Ask About Prior Authorization
Most GLP-1s require prior authorization, even when they're on a plan's formulary. This means your doctor needs to submit documentation showing you meet the plan's criteria, typically a diagnosis of type 2 diabetes, obesity (BMI of 30+), or a qualifying cardiovascular condition.
Step 3: Confirm Your Diagnosis Coding
The diagnosis code your doctor uses on the prescription matters. A GLP-1 prescribed for obesity (ICD-10 code E66) may require a different coverage pathway than one prescribed for type 2 diabetes (E11). Make sure your provider documents your condition accurately.
Step 4: Request a Coverage Exception If Denied
If your plan denies coverage, you have the right to appeal. Your doctor can submit a letter of medical necessity explaining why the GLP-1 is appropriate for your situation. Appeals are granted more often than many patients expect.
What This Milestone Means for Drug Pricing and Access
When 700,000 seniors are enrolled in a program and one company holds 70% of that market, it creates real pricing leverage on both sides. Eli Lilly has an incentive to negotiate favorable terms with Medicare plan sponsors to protect that market share. At the same time, growing competition from Novo Nordisk's semaglutide products creates pressure to keep pricing competitive.
For patients, this competitive dynamic is generally positive. It can translate into better formulary placement, lower copay structures, and expanded access over time.
The $2,000 Part D out-of-pocket cap introduced for 2025 is also significant. Before this change, a senior filling a GLP-1 prescription could face thousands of dollars in annual drug costs even with Part D coverage. The cap provides a real ceiling, though reaching it still requires upfront spending earlier in the year.
If You're Not Yet Covered: Your Options Right Now
Not every senior is among the 700,000 enrolled. If you're a Medicare beneficiary who hasn't been able to access a GLP-1 through your plan, you still have options.
Manufacturer Patient Assistance Programs
Both Eli Lilly and Novo Nordisk offer patient assistance programs for qualifying individuals. Lilly's program, for example, provides Zepbound or Mounjaro at reduced or no cost for people who meet income thresholds. These programs are separate from Medicare and can bridge gaps in coverage.
Medicare Advantage vs. Traditional Medicare
If you're in traditional Medicare with a Part D plan that doesn't cover GLP-1s for obesity, switching to a Medicare Advantage plan during the Annual Enrollment Period (October 15 to December 7 each year) could open new coverage options. Some Medicare Advantage plans have been quicker to add GLP-1 obesity coverage than standalone Part D plans.
Compounded GLP-1s and Telehealth Providers
During periods of FDA-designated shortage, compounded versions of semaglutide and tirzepatide were available through telehealth providers at significantly lower prices. Shortage designations have shifted, so this pathway is narrower than it was in 2023 and 2024. Always verify a provider's legitimacy and confirm the compounding pharmacy's accreditation before proceeding. You can compare vetted telehealth providers through Best Providers.
Coupons and Savings Programs
For Medicare beneficiaries who don't qualify for patient assistance, manufacturer savings cards and third-party coupons can sometimes reduce costs, though these programs often cannot be combined with Medicare benefits. Check GLP-1 Coupons for current options and eligibility details.
Questions to Ask Your Doctor at Your Next Appointment
If you're a senior interested in GLP-1 therapy, the conversation with your doctor is the most important step. Here are specific questions worth asking.
- Which GLP-1 medication do you recommend based on my diagnoses, and is it on my Medicare plan's formulary?
- Will you handle the prior authorization process, and what documentation do you need from me?
- If my plan denies coverage, will you support an appeal or a coverage exception request?
- Are there cardiovascular or kidney-related reasons I might qualify for a GLP-1 beyond just diabetes or weight?
- What monitoring or follow-up will I need after starting the medication?
Bringing these questions prepared signals to your doctor that you've done your research and helps the appointment stay focused on your coverage situation rather than general background information.
No waiting list. No insurance needed.
Frequently Asked Questions
Does Medicare cover GLP-1 medications for weight loss?
As of 2025, some Medicare Part D and Medicare Advantage plans cover GLP-1s for obesity, following a rule change that made this coverage legally permissible. However, coverage is not universal and varies by plan. You need to check your specific plan's formulary and prior authorization requirements.
How do I know if my Medicare plan covers Ozempic, Mounjaro, or Wegovy?
Check your plan's formulary on Medicare.gov or your insurer's website, searching for the drug by brand or generic name. You can also call your plan directly or ask your pharmacist to run a coverage check before your doctor submits the prescription.
What is the out-of-pocket maximum for Medicare Part D in 2025?
Starting in 2025, the Medicare Part D out-of-pocket maximum is capped at $2,000 per year for covered drugs. Once you reach this threshold, your costs for covered prescriptions drop to $0 for the rest of the year.
Why does Eli Lilly dominate Medicare GLP-1 prescriptions?
Eli Lilly's tirzepatide products, Mounjaro for diabetes and Zepbound for obesity, have shown higher average weight loss in clinical trials compared to semaglutide. Lilly has also worked aggressively to secure favorable formulary placements and offers strong patient support programs, contributing to its roughly 70% Medicare market share.
Can I switch to a Medicare Advantage plan to get better GLP-1 coverage?
Yes. Medicare Advantage plans often have different formularies than standalone Part D plans, and some have been faster to add GLP-1 coverage for obesity. You can compare plans and switch during the Annual Enrollment Period from October 15 to December 7 each year.
What if my Medicare plan denies coverage for a GLP-1?
You have the right to appeal a Medicare coverage denial. Your doctor can submit a letter of medical necessity to support your case. Coverage exception requests are granted more often than many patients realize, particularly when there is documented clinical justification.
The Bottom Line for Seniors Considering GLP-1 Therapy
The 700,000-senior milestone is a real signal that Medicare GLP-1 access has moved from a niche exception to something closer to standard practice, at least for specific diagnoses. Eli Lilly's 70% market share reflects tirzepatide's clinical profile and the company's strategic positioning, but it also means that if your doctor leans toward Mounjaro or Zepbound, you're in the majority of the Medicare GLP-1 population.
That said, enrollment numbers don't automatically translate to access for every individual. Your plan, your diagnosis, your doctor's documentation practices, and the appeals process all shape what you actually pay and whether you can access these medications at all.
What to Do Next
Start with your plan's formulary. That single step tells you more about your real-world access than any news headline. If your current plan doesn't cover the GLP-1 your doctor recommends, the Annual Enrollment Period in the fall is your window to switch.
If coverage isn't available through Medicare, don't stop there. Patient assistance programs from Lilly and Novo Nordisk, savings programs, and vetted telehealth providers can provide alternative pathways. The goal is to find the most cost-effective, clinically appropriate route to therapy, and that path looks different for every person.
As always, talk to your physician before starting, changing, or stopping any medication. A doctor who understands your full medical history is the right person to help you weigh the benefits and risks of GLP-1 therapy given your specific situation.
For help navigating your options, GLP-1.com offers provider comparisons, eligibility tools, and a regularly updated coupon database. Whether you're comparing Wegovy vs. Zepbound or looking for the lowest-cost telehealth option, Best Providers and GLP-1 Coupons are good places to start.